Table 2.

JAK inhibitors in dermatologic conditions, route of administration, selectivity and phase of most advanced trial.

STUDY DRUG	RoA	SELECTIVITY	INDICATIONS	STUDY PHASE & STATUS
Tofacitinib	O	JAK-3,1,>>2	PsO	Phase 3 completed
			AA	Phase 4 ongoing
Tofacitinib	T		AD	Phase 2 completed
			PsO	Phase 3 completed
Ruxolitinib	O	JAK-1,2	AA	Phase 2 completed
Ruxolitinib	T		PsO	Phase 2 completed
			vitiligo	Phase 3 ongoing
			AD	Phase 3 ongoing
Baricitinib	O	JAK-1,2	PsO	Phase 2 completed
			AA	Phase 3 ongoing
			AD	Phase 3 completed
			ACD	Phase 1 ongoing
Upadacitinib	O	JAK-1	AD	Phase 3 ongoing
Delgocitinib	T	pan-JAK	AD	Phase 2 ongoing
			DLE	Phase 2 ongoing
			CHE	Phase 2 ongoing
Abrocitinib	O	JAK-1	AD	Phase 3 ongoing
Gusacitinib	O	pan-JAK, SYK	AD	Phase 2 ongoing
Cerdulatinib	T	pan-JAK, SYK	Vitiligo	Phase 2 ongoing
Peficitinib	O	pan-JAK	PsO	Phase 2 completed
Itacitinib	O	JAK-1,2	PsO	Phase 2 completed
			Melanoma	Phase 1 ongoing
			Chronic itch	Phase 2 withdrawn
Filgotinib	O	JAK-1	CLE	Phase 2 completed
Lestaurtinib	O	JAK-2	PsO	Phase 2 completed
PF-06651600	O	JAK-3	AA	Phase 3 ongoing
			Vitiligo	Phase 2 ongoing
BMS-986165	O	TYK2	PsO	Phase 3 ongoing

RoA: route of administration, O: oral, T: topical, PsO: psoriasis, AA: alopecia areata, AD: atopic dermatitis, ACD: allergic contact dermatitis, DLE: discoid lupus erythematosus, CLE: cutaneous lupus erythematosus, CHE: chronic hand eczema.